Literature DB >> 30587493

Imatinib is still recommended for frontline therapy for CML.

Andrew Hantel1, Richard A Larson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30587493      PMCID： PMC6306882          DOI： 10.1182/bloodadvances.2018018614

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  33 in total

Review 1.  Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Authors:  Rena M Conti; William V Padula; Richard A Larson
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

2.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Authors:  David Marin; Alexandra Bazeos; Francois-Xavier Mahon; Lina Eliasson; Dragana Milojkovic; Marco Bua; Jane F Apperley; Richard Szydlo; Ritti Desai; Kasia Kozlowski; Christos Paliompeis; Victoria Latham; Letizia Foroni; Mathieu Molimard; Alistair Reid; Katy Rezvani; Hugues de Lavallade; Cristina Guallar; John Goldman; Jamshid S Khorashad
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Authors:  Gabriel Etienne; Joëlle Guilhot; Delphine Rea; Françoise Rigal-Huguet; Franck Nicolini; Aude Charbonnier; Agnès Guerci-Bresler; Laurence Legros; Bruno Varet; Martine Gardembas; Viviane Dubruille; Michel Tulliez; Marie-Pierre Noel; Jean-Christophe Ianotto; Bruno Villemagne; Martin Carré; François Guilhot; Philippe Rousselot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 4.  Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.

Authors:  Leonardo Campiotti; Matteo Basilio Suter; Luigina Guasti; Rocco Piazza; Carlo Gambacorti-Passerini; Anna Maria Grandi; Alessandro Squizzato
Journal:  Eur J Cancer       Date:  2017-03-30       Impact factor: 9.162

5.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

Authors:  Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Guillermo Garcia-Manero; Alfonso Quintas-Cardama; Jenny Shan; Mary Beth Rios; Farhad Ravandi; Stefan Faderl; Tapan Kadia; Gautam Borthakur; Xuelin Huang; Richard Champlin; Moshe Talpaz; Jorge Cortes
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

6.  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Authors:  L Kalmanti; S Saussele; M Lauseker; M C Müller; C T Dietz; L Heinrich; B Hanfstein; U Proetel; A Fabarius; S W Krause; S Rinaldetti; J Dengler; C Falge; E Oppliger-Leibundgut; A Burchert; A Neubauer; L Kanz; F Stegelmann; M Pfreundschuh; K Spiekermann; C Scheid; M Pfirrmann; A Hochhaus; J Hasford; R Hehlmann
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

7.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Authors:  J Hasford; M Pfirrmann; R Hehlmann; N C Allan; M Baccarani; J C Kluin-Nelemans; G Alimena; J L Steegmann; H Ansari
Journal:  J Natl Cancer Inst       Date:  1998-06-03       Impact factor: 13.506

8.  Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.

Authors:  Roberto Latagliata; Ida Carmosino; Federico Vozella; Paola Volpicelli; Federico De Angelis; Maria Giovanna Loglisci; Adriano Salaroli; Maria Lucia De Luca; Chiara Montagna; Alessandra Serrao; Matteo Molica; Daniela Diverio; Mauro Nanni; Marco Mancini; Massimo Breccia; Giuliana Alimena
Journal:  Hematol Oncol       Date:  2015-12-09       Impact factor: 5.271

9.  Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Authors:  Jonathan Douxfils; Hélène Haguet; François Mullier; Christian Chatelain; Carlos Graux; Jean-Michel Dogné
Journal:  JAMA Oncol       Date:  2016-05-01       Impact factor: 31.777

10.  Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Authors:  Jianxiang Wang; Zhi-Xiang Shen; Giuseppe Saglio; Jie Jin; He Huang; Yu Hu; Xin Du; Jianyong Li; Fanyi Meng; Huanling Zhu; Jianda Hu; Jianmin Wang; Ming Hou; Sabine Hertle; Hans D Menssen; Christine-Elke Ortmann; Catherine Tribouley; Ye Yuan; Michele Baccarani; Xiaojun Huang
Journal:  Blood       Date:  2015-03-12       Impact factor: 22.113
View more
  2 in total

1.  Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.

Authors:  Hélène Haguet; Carlos Graux; François Mullier; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 2.  Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes.

Authors:  Yae Chan Song; Seung Eon Lee; Young Jin; Hyun Woo Park; Kyung-Hee Chun; Han-Woong Lee
Journal:  Mol Cells       Date:  2020-09-30       Impact factor: 5.034
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.